Provided by Tiger Trade Technology Pte. Ltd.

Jasper Therapeutics

1.86
0.0000
Post-market: 1.910.0500+2.69%18:51 EST
Volume:1.40M
Turnover:2.64M
Market Cap:52.05M
PE:-0.32
High:1.96
Open:1.84
Low:1.81
Close:1.86
52wk High:22.99
52wk Low:1.39
Shares:27.98M
Float Shares:22.81M
Volume Ratio:1.91
T/O Rate:6.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.7868
EPS(LYR):-4.8865
ROE:-191.12%
ROA:-72.92%
PB:4.50
PE(LYR):-0.38

Loading ...

BUZZ-Jasper Therapeutics jumps as asthma drug shows early promise

Reuters
·
Dec 02

Jasper Therapeutics Inc: Briquilimab Was Well Tolerated in Study, Demonstrating a Favorable Safety Profile

THOMSON REUTERS
·
Dec 02

Jasper Therapeutics Reports Positive Preliminary Data From Etesian Study of Briquilimab in Asthma and Findings From Beacon Study Internal Investigation

THOMSON REUTERS
·
Dec 02

Jasper Therapeutics Inc: Completion of Internal Beacon Study Investigation Noting No Deviations or Issues With Drug Product Utilized

THOMSON REUTERS
·
Dec 02

NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM

Reuters
·
Dec 02

Jasper Therapeutics to Present Preliminary Asthma and Urticaria Study Data in Investor Webinar

Reuters
·
Dec 02

Jasper Therapeutics Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
Nov 11

Jasper Therapeutics Showcases Briquilimab’s Strong Efficacy and Safety in Chronic Urticaria

Reuters
·
Nov 11

CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says

Benzinga_recent_news
·
Nov 11

RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
Nov 11

Jasper Therapeutics (JSPR) Receives a Hold from William Blair

TIPRANKS
·
Nov 11

Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating

TIPRANKS
·
Nov 11

Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts

TIPRANKS
·
Nov 11

Jasper Therapeutics Q3 loss smaller than estimates

Reuters
·
Nov 10

Jasper Therapeutics Q3 EPS $(1.13) Beats $(1.28) Estimate

Benzinga
·
Nov 10

Jasper Therapeutics posts $18.7 million net loss for third quarter 2025

Reuters
·
Nov 10

Jasper Therapeutics Inc - Plan to Report Initial Data From Etesian Study in Allergic Asthma in Q4

THOMSON REUTERS
·
Nov 10

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 10

Jasper Therapeutics to Present at UBS Global Healthcare Conference

Reuters
·
Nov 04

Jasper Therapeutics Inc expected to post a loss of $1.21 a share - Earnings Preview

Reuters
·
Nov 03